Physician profile
Erwin Danzer
NPI 1831349653
$4,093.21
in general payments reported to CMS, 2019-2025
16 companies · $1,060 in 2025
The $1,060 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,005 · 2022: $778 · 2023: $604 · 2024: $647 · 2025: $1,060.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,310.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,310.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,011.69 | 2021-2025 | |
| Bioventus LLC | $577.86 | 2021-2023 | Durolane |
| Lundbeck LLC | $558.69 | 2023-2025 | Vyepti |
| Pfizer INC. | $350.19 | 2021-2025 | |
| Eisai INC. | $117.18 | 2021-2022 | |
| Vertex Pharmaceuticals Incorporated | $114.03 | 2025 | |
| Biohaven Pharmaceuticals, INC. | $78.66 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $59.52 | 2021-2023 | Ajovy |
| Biohaven Pharmaceutical Holding Company Ltd. | $45.92 | 2022 | |
| Allergan, INC. | $40.74 | 2021-2022 | |
| Hikma Pharmaceuticals USA | $35.72 | 2022 | |
| Averitas Pharma INC. | $24.11 | 2024 | Qutenza |
| Ibsa Pharma INC. | $23.24 | 2021 | |
| Abbott Laboratories | $22.90 | 2022 | |
| Lilly USA, LLC | $17.64 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $15.12 | 2025 | Breyanzi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erwin Danzer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.